• Regulatory NewsRegulatory News

    Cavazzoni discusses CDER staffing, FY2023 budget priorities

    The US Food and Drug Administration’s (FDA) budget request for FY2023 reflects a focus on combatting the nation’s opioid epidemic and improving postmarket surveillance, said Patrizia Cavazzoni, director of FDA’s Center for Drugs Evaluation and Research (CDER). Also, after a low attrition rate during the pandemic, vacancies are now trending upward as CDER staff is departing for new opportunities, she said on call with the Alliance for a Stronger FDA on Monday.   The FDA...
  • Regulatory NewsRegulatory News

    FDA's FY2022 Senate funding bill clears Appropriations committee

    The Senate Appropriations committee has completed its markup of the FY2022 budget for the US Food and Drug Administration (FDA), advancing by a 25-5 vote a bill that would hold the agency to a $200 million increase in its budget authority.   The bill exited the Appropriations subcommittee responsible for FDA funding on Monday with no objections to the Senate’s proposed 6% increase for the agency over FY2021 figures. (RELATED: Senate subcommittee advances FY2022 FDA f...
  • Regulatory NewsRegulatory News

    FDA’s FY22 budget priorities: boost inspections, surveillance; avert device shortages

    The US Food and Drug Administration’s FY 2022 budget request to Congress indicates the agency’s wishes to catch up on the backlog of inspections that have been delayed due to COVID-19, improve its drug surveillance efforts to detect possible shortages, and avert shortages for such medical devices as personal protective equipment (PPE).   Many of these requests have been driven by the need to combat device and drug shortages wrought by the pandemic.   The request al...
  • Regulatory NewsRegulatory News

    Biden’s first budget request seeks $6.5 billion for FDA

    The US Food and Drug Administration (FDA) is seeking $6.5 billion in funding for FY2022 under President Joe Biden’s $6 trillion budget proposal announced on Friday, an overall increase of $477 million (8%) over the agency’s FY2021 budget.   In a news release, the agency said the $6.5 billion budget would be used for “investments in critical public health infrastructure, core food safety and medical product safety programs and other vital public health programs,” which ...
  • Regulatory NewsRegulatory News

    House committee proposes $500M in COVID funding for FDA

    The House Energy and Commerce Committee will convene Thursday to markup its portions of the budget reconciliation bill that will contain President Joe Biden’s proposed $1.9 trillion COVID-19 relief package.   The budget reconciliation process was created under the Congressional Budget Act of 1974 and enables Congress to fast-track legislation related to taxes, spending and debt limits. Democrats have opted to use the process to allow them to pass the stimulus package...
  • Regulatory NewsRegulatory News

    Trump’s 2020 Budget Seeks FDA Tweaks to Increase Generic Competition

    With Democrats controlling the House, the specifics of President Donald Trump’s Fiscal 2020 budget, released on Monday, may not matter much, but it does feature new attempts to alter US Food and Drug Administration (FDA) processes in order to increase generic drug competition. Similarly to last year’s budget , the 2020 budget looks to save more than $1 billion in Medicare and Medicaid funds by stopping some generic drug applicants, who file first and win tentative appr...
  • Regulatory NewsRegulatory News

    Update: Appropriations Bill Would Give FDA $269M Boost Over FY2018 Budget

    The House and Senate passed a seven-bill spending package on Thursday to fund large portions of the federal government through FY2019. And President Donald Trump has said he will sign the bill.   The spending package comes near the end of a three-week stopgap funding measure to allow the government to reopen after a record 35-day partial government shutdown that began on 22 December 2018 after President Donald Trump refused to sign a short-term spending bill over his...
  • Feature ArticlesFeature Articles

    A New Regulatory Paradigm for Medical Devices in India

    This article explains medical device classification rules, manufacturer registration procedures, dossier filing procedures, and pre-clinical and marketing application approval processes. Introduction Medical devices are a multi-billion-dollar global industry with continuous growth opportunities due to advancements in technology and new innovations. However, innovations and new advancements do not always reach patients due to a lack of clarity related to the approval p...
  • Regulatory NewsRegulatory News

    Senate Appropriations Bill Maintains FDA Funding for 2018

    The Senate Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies on Tuesday voted to advance its draft FY2018 appropriations bill, which includes $2.8 billion in discretionary funding for the US Food and Drug Administration (FDA). The full Appropriations Committee is scheduled to meet Thursday to mark up the bill before voting to advance it to the Senate for consideration. While the funding levels in the bill d...
  • Regulatory NewsRegulatory News

    House Drafts FY 2018 FDA Budget With Same Appropriation Levels as 2017

    The House Appropriations Committee on Tuesday released the fiscal year 2018 Agriculture Appropriations bill, which would enact a total of $2.8 billion in discretionary funding for the US Food and Drug Administration (FDA). That level of appropriations, which stands in stark contrast to President Donald Trump’s call to eliminate appropriations for FDA and run the agency entirely on industry user fees, would continue FDA’s budget authority (BA) appropriations at the...
  • Regulatory NewsRegulatory News

    Asia Regulatory Roundup: Australia Opens Priority Review Pathway (27 June 2017)

    Welcome to our Asia Regulatory Roundup, our weekly overview of the top regulatory news in Asia. TGA Starts Accepting Priority Review Notifications, Implements Revised Orphan Drug Program The Therapeutic Goods Administration (TGA) of Australia has opened its priority review pathway. TGA is now accepting notifications from sponsors who plan to apply for priority review status to accelerate the approval of their medicines in the coming months. Officials at TGA are ...
  • Regulatory NewsRegulatory News

    FDA Commissioner Vows to Eliminate Backlog of Orphan Drug Designation Requests

    At a Senate hearing on President Donald Trump's FY2018 budget request for the US Food and Drug Administration (FDA), Commissioner Scott Gottlieb vowed to eliminate the backlog of orphan drug designation requests and said he will soon release "modern and risk-based" tools for assessing new treatments, especially for rare diseases and conditions with no effective treatments. "Right now we have a backlog of about 200 orphan drug designation requests where we haven't respond...